Quanta is advancing 2 clinical trials from its pipeline of KRAS G12D-focused drug candidates, as monotherapy and combination with EGFR inhibitors
“Strong anti-tumor activity, favorable oral bioavailability and drug-like properties demonstrated in preclinical models “ “Data support ongoing IND-enabling studies for planned clinical...
Quanta Therapeutics Announces Late-Breaking Presentation of QTX3544
QTX3034, G12D-preferring multi-KRAS inhibitor, IND received clearance by US FDA to begin Phase 1 study; planned for 1Q24; and other pipeline updates
The combination of QTX3034, a multi-KRAS inhibitor, and EGFR inhibitors demonstrated potent, synergistic anti-tumor activity in preclinical studies.
Quanta Therapeutics will bring its KRAS inhibitors into the clinic next year with a fresh heap of $50.7 million from blue-chip investors as it looks to catch up to the KRAS leaders and take the difficult class into other mutations and broader areas of oncology.
RADNOR, Pa. & SOUTH SAN FRANCISCO, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held biopharmaceutical company pioneering targeted therapies to treat RAS-driven cancers, today announced a $50.7 million Series D financing. The financing was led by Avidity Partners and was supported by Quanta’s existing investors including Sofinnova Investments, Vida Ventures, Surveyor Capital (a Citadel company), Longitude Capital, BVF Partners and AbbVie Ventures. Other new participants were GC&H Investments (the partner fund of Cooley LLP) and WS Investment Company (Wilson Sonsini’s venture arm). The Series D funding brings the total amount raised since inception to over $142 million.
Quanta Therapeutics Presents Data from KRAS Inhibitor Pipeline at Annual AACR Meeting in Late-Breaking Research Session
Quanta Therapeutics Announces Two Late-Breaking Preclinical Presentations from KRAS Inhibitor Pipeline at Annual AACR Meeting
Quanta Therapeutics Appoints Leonardo Faoro, MD, as Chief Medical Officer